CME in Minutes: Education in Cardiology & Pulmonology

Answers In CME
  • 4,7 (3)
  • KHOA HỌC ĐỜI SỐNG
  • HẰNG TUẦN
CME in Minutes: Education in Cardiology & Pulmonology

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Cardiology & Pulmonology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for busy healthcare professionals to cover the diagnosis, treatment, follow-up, and clinical management of conditions in cardiology, pulmonology. Earning your CME/CE credit has never been faster or easier. Download the URL for each individual program to request continuing education credit or access the slides.

  1. 12 THG 12

    David Harpole, MD / Alfredo Addeo, MD - The Possibilities of Perioperative: Assessing the Use of Perioperative Immunotherapy for Resectable NSCLC

    Please visit answersincme.com/860/94256783-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss the rationale and strategies for integrating perioperative immunotherapeutic approaches to resectable NSCLC care plans, and a patient joins the conversation to share her story. Upon completion of this activity, participants should be better able to: Explain the rationale for perioperative immunotherapeutic approaches in the treatment landscape of resectable non-small cell lung cancer (rNSCLC); and Identify when perioperative immunotherapeutic approaches should be considered for patients with rNSCLC.

    1 phút

  2. 12 THG 12

    Stella Lee, MD - Biologic Therapies for Chronic Rhinosinusitis With Nasal Polyps: Practical, Patient-Centered Perspectives for Providers

    Please visit answersincme.com/YWD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in rhinology discusses the use of biologics for the management of chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Identify key considerations for initiating a biologic therapy in patients with CRSwNP; Discuss the clinical impact of the latest data for novel approved biologics in CRSwNP; and Apply best practice approaches for management of biologics in patients with CRSwNP. This activity is intended for US healthcare professionals only.

    19 phút

  3. 29 THG 11

    Csaba P. Kovesdy, MD - Integrating Nonsteroidal MRAs in Practice: A Guideline-Driven Approach to the Management of CKD and T2D

    Please visit answersincme.com/YTP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in cardiology and nephrology discuss the latest evidence and guidance on the use of nonsteroidal mineralocorticoid receptor antagonist (MRA) for the treatment of cardio-renal-metabolic conditions. Upon completion of this activity, participants should be better able to: Identify patients with type 2 diabetes (T2D) who are at high risk for chronic kidney disease (CKD) progression and cardiovascular events; Outline the clinical implications of updated CKD guidelines regarding the use of nonsteroidal MRA therapy in patients with T2D and CKD; and Describe the latest evidence on the use of nonsteroidal MRA therapies in individuals with cardio-renal-metabolic conditions.

    16 phút

  4. 26 THG 11

    David Harpole, MD / Neel Chudgar, MD - The Practicalities of Perioperative Immunotherapy for Resectable NSCLC

    Please visit answersincme.com/860/94256783-replay3 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss practical considerations for management of resectable NSCLC with perioperative immunotherapeutic regimens, and an NSCLC survivor joins the conversation to share her perspective on the treatment journey. Upon completion of this activity, participants should be better able to: Identify when perioperative immunotherapeutic approaches should be considered for patients with resectable NSCLC (rNSCLC); and Outline strategies for the optimization of long-term management of rNSCLC with perioperative immunotherapeutic regimens.

    24 phút

  5. 20 THG 11

    David Harpole, MD / Nicolas Girard, MD, PhD - Trials and Tribulations: Examining the Data for Perioperative Immunotherapeutic Approaches in Resectable NSCLC

    Please visit answersincme.com/860/94256783-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in non–small-cell lung cancer (NSCLC) discuss the clinical significance of the latest efficacy and safety data for perioperative immunotherapeutic regimens for resectable NSCLC. Upon completion of this activity, participants should be better able to: Review the significance of the latest clinical data of perioperative immunotherapeutic approaches in patients with resectable NSCLC (rNSCLC); and Outline strategies for the optimization of long-term management of rNSCLC with perioperative immunotherapeutic regimens.

    31 phút

  6. 20 THG 9

    Stephanie A. Christenson, MD, MAS - ​Targeting Eosinophils for Fewer Exacerbations:​ The Future of Biologic Treatments in COPD Management

    Please visit answersincme.com/PES860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pulmonary disease discusses the implications of the latest evidence on biologic therapies targeting type 2 inflammation for the treatment of chronic obstructive pulmonary disease (COPD). Upon completion of this activity, participants should be better able to: Identify the rationale for investigating biologics targeting type 2 inflammation for the treatment of patients with chronic obstructive pulmonary disease (COPD); Review the clinical impact of emerging biologics in the treatment of eosinophilic COPD in patients at high risk of exacerbations; Outline strategies to implement biologics targeting type 2 eosinophilic inflammation into clinical practice, as they become available. This activity is intended for US healthcare professionals only.

    14 phút

  7. 9 THG 9

    Leonard B. Bacharier, MD - Highlighting the Use of Biologics in Pediatric Patients: Case Scenarios to Elevate Asthma Treatment

    Please visit answersincme.com/YCT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in pediatric asthma discusses early intervention with biologic therapy for children with moderate to severe asthma. Upon completion of this activity, participants should be better able to: Recognize pediatric patients with asthma who may benefit from treatment intensification with biologic therapy; Outline the clinical impact of add-on biologics approved for the treatment of pediatric patients with moderate to severe asthma; and Identify patient-centered strategies to optimize outcomes for pediatric patients with inadequately controlled moderate to severe asthma. This activity is intended for US healthcare professionals only.

    17 phút

  8. 9 THG 9

    Mark Awad, MD, PhD - Advancing the Therapeutic Landscape of SCLC with B7-H3–Targeted Antibody-Drug Conjugates: Insights and Future Directions

    Please visit answersincme.com/BXP860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in thoracic oncology discusses B7-H3–directed antibody-drug conjugates as a treatment strategy for small-cell lung cancer. Upon completion of this activity, participants should be better able to: Recognize the rationale for developing antibody-drug conjugates (ADCs) targeting B7-H3 as treatment for extensive-stage small-cell lung cancer (ES-SCLC); Review the preliminary efficacy and safety data for emerging B7-H3–directed ADCs for the treatment of pretreated ES-SCLC; and Describe key clinical considerations for the future use of B7-H3–directed ADCs in ES-SCLC.

    13 phút
Xem tất cả (52)

Xếp Hạng & Nhận Xét

4,7
/5
3 Xếp hạng

Giới Thiệu

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Cardiology & Pulmonology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for busy healthcare professionals to cover the diagnosis, treatment, follow-up, and clinical management of conditions in cardiology, pulmonology. Earning your CME/CE credit has never been faster or easier. Download the URL for each individual program to request continuing education credit or access the slides.

Thông Tin

Nội Dung Khác Của Answers In CME

Bạn cần đăng nhập để nghe các tập có chứa nội dung thô tục.

Luôn cập nhật thông tin về chương trình này

Đăng nhập hoặc đăng ký để theo dõi các chương trình, lưu các tập và nhận những thông tin cập nhật mới nhất.
Chọn quốc gia hoặc vùng

Châu Phi, Trung Đông và Ấn Độ

Châu Á Thái Bình Dương

Châu Âu

Châu Mỹ Latinh và Caribê

Hoa Kỳ và Canada